Endocrine Abstracts

Background: Targeted therapy using phosphatidylinositol 3-kinase (PI3K) inhibitors has become widespread in the treatment of cancers. Although PI3K inhibitors raised concern about the alteration of glucose and lipid metabolism from animal studies, human clinical data have been rarely reported.Aim: We investigated the clinical manifestations, incidence of diabetes and its predictive factors in cancer patients who treated with PI3K inhibitors.<p class=...